Defining the role of Taiman, the Drosophila homolog of AIB1, as a super-competitor in developing epithelia

定义 Taiman(AIB1 的果蝇同源物)作为上皮细胞发育中超级竞争者的作用

基本信息

  • 批准号:
    10626071
  • 负责人:
  • 金额:
    $ 4.77万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2021
  • 资助国家:
    美国
  • 起止时间:
    2021-05-01 至 2024-04-30
  • 项目状态:
    已结题

项目摘要

PROJECT SUMMARY Invasive breast cancer is a deadly disease, killing ~42,000 women each year and costing the United States over $16.5 billion annually. The complicated disease mechanisms that drive breast cancer are still insufficiently understood to confidently design therapeutics. One mechanism emerging as a potential driver for local invasion in breast and other cancers is ‘cell competition.’ This phenomenon occurs when two different cell populations with different ‘fitness’ levels are juxtaposed in the same tissue. High fitness cells (called ‘winners’) grow more rapidly and kill off slower growing neighbors (called ‘losers’) by apoptosis. Cancer cells acquire ‘winner’ status by activating oncogenes. Oncogenes that confer ‘winner’ status are called ‘super-competitors.’ Our lab uses the model organism, Drosophila melanogaster, to study conserved growth and proliferation pathways that are altered in human cancer. In previous work we showed that Drosophila Taiman (Tai, AIB1 in humans), a co-activator of the Ecdysone steroid hormone receptor (EcR), is a candidate super-competitor and imparts ‘winner’ status to cells via production of the secreted, pro-apoptotic protein Spätzle (Spz), a Toll receptor ligand. We have also shown that Tai binds the Yorkie (Yki) coactivator protein, the main target of the Hippo tumor suppressor pathway, and that Yki:Tai collaboratively drive expression of pro-growth genes. However, we do not fully understand how Tai drives neighbor killing, or whether it requires interactions with EcR and/or Yki. Moreover, classifying Tai as a ‘super-competitor’ requires evidence that lowering the Tai dose confers ‘loser’ status relative to wildtype cells. In the following three Aims, I will test my hypothesis that Tai acts as a super-competitor through either its interaction with Yki (Hippo pathway) or EcR (ecdysone pathway), test the relative fitness of Tai-overexpressing (Taihigh), wildtype (Taiwt), and Tai hypomorphic (Tailow) cells, and carry out experiments to identify cell competition factors regulated by Tai. In Aim 1, I will assess the effects of elevated or reduced Tai on cell survival in homotypic vs. heterotypic environments. To link to our published data, I will also investigate the requirement of the Spz/Toll pathway in these contexts. In Aim 2, I will use candidate-based approaches to test the requirements for Yki/Hippo and EcR signaling in Tai-driven killing of neighbor cells. Finally in Aim 3, I will use the unbiased, discovery-based method Translating Ribosome Affinity Purification with sequencing (TRAP-Seq) to identify the Tai-induced translated proteome in wing cells and candidate ‘competition’ factors within it. These aims will define the molecular mechanisms underlying Tai-regulated cell competition in epithelial tissue. This work could also reveal a link between cell competition and steroid hormone signaling, which could be a novel element of cancer biology. The pathways that will be uncovered by this work will have long-term impacts, as knowledge of cell competition mechanisms could be applied to mammalian models to learn more about cancer emergence and progression. Specifically, knowledge gained from this research could lead to greater understanding of the role of the human homolog AIB1 in breast cancer and lead to the development of potential new therapeutics.
项目总结

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Colby Kristina Schweibenz其他文献

Colby Kristina Schweibenz的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Colby Kristina Schweibenz', 18)}}的其他基金

Defining the role of Taiman, the Drosophila homolog of AIB1, as a super-competitor in developing epithelia
定义 Taiman(AIB1 的果蝇同源物)作为上皮细胞发育中超级竞争者的作用
  • 批准号:
    10455430
  • 财政年份:
    2021
  • 资助金额:
    $ 4.77万
  • 项目类别:

相似海外基金

Linkage of HIV amino acid variants to protective host alleles at CHD1L and HLA class I loci in an African population
非洲人群中 HIV 氨基酸变异与 CHD1L 和 HLA I 类基因座的保护性宿主等位基因的关联
  • 批准号:
    502556
  • 财政年份:
    2024
  • 资助金额:
    $ 4.77万
  • 项目类别:
Olfactory Epithelium Responses to Human APOE Alleles
嗅觉上皮对人类 APOE 等位基因的反应
  • 批准号:
    10659303
  • 财政年份:
    2023
  • 资助金额:
    $ 4.77万
  • 项目类别:
Deeply analyzing MHC class I-restricted peptide presentation mechanistics across alleles, pathways, and disease coupled with TCR discovery/characterization
深入分析跨等位基因、通路和疾病的 MHC I 类限制性肽呈递机制以及 TCR 发现/表征
  • 批准号:
    10674405
  • 财政年份:
    2023
  • 资助金额:
    $ 4.77万
  • 项目类别:
An off-the-shelf tumor cell vaccine with HLA-matching alleles for the personalized treatment of advanced solid tumors
具有 HLA 匹配等位基因的现成肿瘤细胞疫苗,用于晚期实体瘤的个性化治疗
  • 批准号:
    10758772
  • 财政年份:
    2023
  • 资助金额:
    $ 4.77万
  • 项目类别:
Identifying genetic variants that modify the effect size of ApoE alleles on late-onset Alzheimer's disease risk
识别改变 ApoE 等位基因对迟发性阿尔茨海默病风险影响大小的遗传变异
  • 批准号:
    10676499
  • 财政年份:
    2023
  • 资助金额:
    $ 4.77万
  • 项目类别:
New statistical approaches to mapping the functional impact of HLA alleles in multimodal complex disease datasets
绘制多模式复杂疾病数据集中 HLA 等位基因功能影响的新统计方法
  • 批准号:
    2748611
  • 财政年份:
    2022
  • 资助金额:
    $ 4.77万
  • 项目类别:
    Studentship
Genome and epigenome editing of induced pluripotent stem cells for investigating osteoarthritis risk alleles
诱导多能干细胞的基因组和表观基因组编辑用于研究骨关节炎风险等位基因
  • 批准号:
    10532032
  • 财政年份:
    2022
  • 资助金额:
    $ 4.77万
  • 项目类别:
Recessive lethal alleles linked to seed abortion and their effect on fruit development in blueberries
与种子败育相关的隐性致死等位基因及其对蓝莓果实发育的影响
  • 批准号:
    22K05630
  • 财政年份:
    2022
  • 资助金额:
    $ 4.77万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Investigating the Effect of APOE Alleles on Neuro-Immunity of Human Brain Borders in Normal Aging and Alzheimer's Disease Using Single-Cell Multi-Omics and In Vitro Organoids
使用单细胞多组学和体外类器官研究 APOE 等位基因对正常衰老和阿尔茨海默病中人脑边界神经免疫的影响
  • 批准号:
    10525070
  • 财政年份:
    2022
  • 资助金额:
    $ 4.77万
  • 项目类别:
Leveraging the Evolutionary History to Improve Identification of Trait-Associated Alleles and Risk Stratification Models in Native Hawaiians
利用进化历史来改进夏威夷原住民性状相关等位基因的识别和风险分层模型
  • 批准号:
    10689017
  • 财政年份:
    2022
  • 资助金额:
    $ 4.77万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了